Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to -$2.0 million.

  • Zenas BioPharma's Change in Account Payables fell 15760.61% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.7 million, marking a year-over-year decrease of 16079.03%. This contributed to the annual value of $11.7 million for FY2024, which is 290861.24% up from last year.
  • According to the latest figures from Q3 2025, Zenas BioPharma's Change in Account Payables is -$2.0 million, which was down 15760.61% from -$12.1 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Change in Account Payables ranged from a high of $5.4 million in Q4 2024 and a low of -$12.1 million during Q2 2025
  • Moreover, its 3-year median value for Change in Account Payables was $3.0 million (2023), whereas its average is $462625.0.
  • Per our database at Business Quant, Zenas BioPharma's Change in Account Payables skyrocketed by 7375.0% in 2024 and then crashed by 241812.5% in 2025.
  • Over the past 3 years, Zenas BioPharma's Change in Account Payables (Quarter) stood at $3.1 million in 2023, then soared by 73.75% to $5.4 million in 2024, then plummeted by 136.05% to -$2.0 million in 2025.
  • Its Change in Account Payables stands at -$2.0 million for Q3 2025, versus -$12.1 million for Q2 2025 and $2.9 million for Q1 2025.